IRIS
UCCELLI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 25.139
Totale 25.139
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 25.139
Totale 25.139
Salva come PNG Salva come JPEG
Città #
Genova 19.862
Rapallo 2.878
Genoa 2.313
Bordighera 86
Totale 25.139
Salva come PNG Salva come JPEG
Nome #
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. 204
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 185
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 182
Adult stem cells for spinal cord injury: what types and how do they work? 171
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. 171
Neuroprotective features of mesenchymal stem cells. 168
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 158
Immunotherapy for neurological diseases. 155
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. 154
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 153
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. 150
Unveiling the enigma of the CNS as a B-cell fostering environment. 150
Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. 150
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 149
Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. 148
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 147
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 146
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 146
IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways 146
Quantitative 3D investigation of Neuronal network in mouse spinal cord model 145
Neurorepair with mesenchymal stem cells: hope or hype? 144
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 144
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 144
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 142
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 142
Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. 142
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 141
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 141
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 140
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 140
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 139
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation 138
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 138
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 137
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 136
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 134
Stem cells for multiple sclerosis: promises and reality. 133
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 133
Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? 132
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 132
Sirt6 regulates dendritic cell differentiation, maturation, and function 130
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 129
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 129
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 128
Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. 128
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 128
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. 127
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 126
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 126
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. 126
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 126
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. 126
Different MRI patterns in MS worsening after stopping fingolimod 125
Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis 125
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 123
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. 123
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 123
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 122
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 121
A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 121
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 119
Primary varicella zoster infection associated with fingolimod treatment. 119
Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. 119
NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation 119
X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model 118
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 118
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 117
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. 117
Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. 116
Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis 116
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. 116
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. 116
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 116
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 115
Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. 115
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 114
Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. 114
T-cell trafficking in the central nervous system. 114
Interindividual variability of cranioencephalic relationships as predicted by CT. 113
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. 113
Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). 113
Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form. 113
Costs and quality of life of multiple sclerosis in Italy. 112
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS 112
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 112
Central and peripheral nervous system complications following allogeneic bone marrow transplantation. 112
Anti-Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia 112
Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. 111
Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. 111
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 110
Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography 110
Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. 110
Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. 109
Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. 109
Teriflunomide treatment reduces B cells in patients with MS. 109
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. 108
Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. 108
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 108
Reward responsiveness and fatigue in multiple sclerosis. 108
Demyelination and axonal damage in a non-human primate model of multiple sclerosis. 107
Totale 12.990
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.026
article - articoli 66.172
book - libri 310
conference - conferenze 4.298
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.246
Totale 146.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.390 0 0 0 0 0 0 0 0 0 0 743 647
2019/20207.550 336 212 277 517 674 891 1.219 606 724 1.127 719 248
2020/20212.373 169 199 233 221 147 200 149 230 193 291 169 172
2021/20223.469 107 213 319 457 152 193 143 755 174 317 118 521
2022/20233.468 329 292 41 362 558 581 21 221 593 37 362 71
2023/20241.887 110 246 70 274 181 405 239 158 126 72 6 0
Totale 25.727